Endo agrees to pull opioid medicine from the market
Endo International said Thursday it will comply with a request by the Food and Drug Administration to voluntarily pull Opana ER from the market.
In a statement, the company said it “continues to believe in the safety, efficacy, and favorable benefit-risk profile of Opana ER, when used as intended." Endo also noted it has taken “significant steps” over the years to combat misuse and abuse of its opioid-based products.
“Nevertheless , after careful consideration and consultation with the FDA…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: John George Source Type: news
More News: Food and Drug Administration (FDA) | Health Management | Opana | Pharmaceuticals | Substance Abuse